Recombinant antibody technology has been leveraged to mitigate a range of common problems associated with hybridoma platforms, helping to facilitate the development of an entirely new class of ...

PRESS RELEASE Strategic research collaboration to advance MTx’s recombinant polyclonal IgG technologyAgreement includes R&D funding for ...

The development of early monoclonal antibody (mAb) therapies centered around the hybridoma platform requires the production of target antigen or immunogen and animal immunizations. This means there ...

A new study in the journal Human Gene Therapy indicates that DNA impurities derived from plasmid and host cell DNA are encapsulated into recombinant adeno-associated virus (rAAV) capsids as ...

Recombinant antibody technology has addressed many problems associated with hybridoma-based platforms, opening the door to a new class of biologics. Today, this technology continues to contribute to ...

The host cell system is a critical determinant of recombinant protein quality and yield, with direct influence on protein folding and post-translational modification factors that shape the ...

Epigenome editing has followed a similar path, in that more recent technological breakthroughs have enabled scientists to apply the discoveries made in previous decades. Epigenome editing performs a ...

A clinical review of a novel blood test use in rural Alabama for multi-cancer detection, analyzing methylation patterns of cell-free DNA and future strategies. This is an ASCO Meeting Abstract from ...

The first peer-reviewed journal in the field of human gene therapy, providing all-inclusive coverage of the research, methods, and clinical developments that are driving today's explosion of gene ...